search
Back to results

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

Primary Purpose

Acute Otitis Media

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Drug: OP0201 20mg
Drug: Placebo 0mg
Sponsored by
Novus Therapeutics, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Acute Otitis Media

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria includes but is not limited to:

  1. AOM diagnosis with moderate to severe bulging of the TM and recent (< 48 hours [h]) onset of ear pain.
  2. Moderate to severe ear pain in the affected ear(s), defined as a score of ≥ 5 (on a scale of 0 10) on the NRS 11 as evaluated by the subject at Screening.
  3. Generally good health (other than AOM) as determined by evaluation of medical history and physical examination at Screening.
  4. Negative urine pregnancy test at Screening for all female subjects of childbearing potential.
  5. Able to read and sign written informed consent prior to study participation.

Exclusion Criteria includes but is not limited to:

  1. Presence of a perforated TM at Screening or had a perforated TM within 6 months (mo) prior to Screening as determined by medical history
  2. Subjects with tympanostomy tubes
  3. Acute or chronic otitis externa
  4. Chronic otitis media defined as confirmed presence of middle ear effusion for 12 weeks or longer
  5. Disorders with decreased mucociliary clearance or higher viscosity of the mucous (eg, cystic fibrosis, primary ciliary dyskinesia, Kartagener's syndrome)
  6. Clinically relevant blockage of 1 or both nasal passages, as determined by the investigator's medical judgment
  7. Permanent hearing loss irrespective of otitis media
  8. Subjects with medical conditions that may affect interpretation of the safety or efficacy of study drug as determined by the investigator's medical judgment
  9. Subjects with craniofacial abnormalities (eg, cleft palate, Down's Syndrome)
  10. Subjects with erythema of the TM without other evidence of otitis media
  11. Seborrheic dermatitis involving the affected external ear canal or pinna
  12. Use of medications with known vasoconstrictive properties (eg, decongestants [Afrin®, Sudafed®]) currently or within 2 h prior to Screening
  13. Use of oral analgesics < 2 h prior to Screening or Baseline (oral analgesics > 2 h are permitted as long as ear pain criteria are met per Inclusion Criteria)

Sites / Locations

  • US Clinical Research Group, LLC.
  • Vista Health Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Drug: OP0201

Drug: Placebo

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants With Adverse Events

Secondary Outcome Measures

Full Information

First Posted
December 3, 2018
Last Updated
November 21, 2019
Sponsor
Novus Therapeutics, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT03766373
Brief Title
Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media
Official Title
Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
January 7, 2019 (Actual)
Primary Completion Date
January 30, 2019 (Actual)
Study Completion Date
January 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novus Therapeutics, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the Safety and Reduction of Ear Pain in Adults with Acute Otitis Media.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Otitis Media

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Drug: OP0201
Arm Type
Active Comparator
Arm Title
Drug: Placebo
Arm Type
Placebo Comparator
Intervention Type
Combination Product
Intervention Name(s)
Drug: OP0201 20mg
Intervention Description
OP0201
Intervention Type
Combination Product
Intervention Name(s)
Drug: Placebo 0mg
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Number of Participants With Adverse Events
Time Frame
1 Day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria includes but is not limited to: AOM diagnosis with moderate to severe bulging of the TM and recent (< 48 hours [h]) onset of ear pain. Moderate to severe ear pain in the affected ear(s), defined as a score of ≥ 5 (on a scale of 0 10) on the NRS 11 as evaluated by the subject at Screening. Generally good health (other than AOM) as determined by evaluation of medical history and physical examination at Screening. Negative urine pregnancy test at Screening for all female subjects of childbearing potential. Able to read and sign written informed consent prior to study participation. Exclusion Criteria includes but is not limited to: Presence of a perforated TM at Screening or had a perforated TM within 6 months (mo) prior to Screening as determined by medical history Subjects with tympanostomy tubes Acute or chronic otitis externa Chronic otitis media defined as confirmed presence of middle ear effusion for 12 weeks or longer Disorders with decreased mucociliary clearance or higher viscosity of the mucous (eg, cystic fibrosis, primary ciliary dyskinesia, Kartagener's syndrome) Clinically relevant blockage of 1 or both nasal passages, as determined by the investigator's medical judgment Permanent hearing loss irrespective of otitis media Subjects with medical conditions that may affect interpretation of the safety or efficacy of study drug as determined by the investigator's medical judgment Subjects with craniofacial abnormalities (eg, cleft palate, Down's Syndrome) Subjects with erythema of the TM without other evidence of otitis media Seborrheic dermatitis involving the affected external ear canal or pinna Use of medications with known vasoconstrictive properties (eg, decongestants [Afrin®, Sudafed®]) currently or within 2 h prior to Screening Use of oral analgesics < 2 h prior to Screening or Baseline (oral analgesics > 2 h are permitted as long as ear pain criteria are met per Inclusion Criteria)
Facility Information:
Facility Name
US Clinical Research Group, LLC.
City
Bellflower
State/Province
California
ZIP/Postal Code
90706
Country
United States
Facility Name
Vista Health Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://novustherapeutics.com/
Description
Related Info

Learn more about this trial

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

We'll reach out to this number within 24 hrs